NCT05352893Phase 3Completed

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Study sponsor: Vanda Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-08-17Actual
Enrollment · participants45Actual
Source updated2026-03-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear). After: Measure: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear). After: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview